Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Precision oncology in metastatic colorectal cancer — from biology to medicine

Open access
Di Nicolantonio, Federica, Vitiello, Pietro Paolo, Marsoni, Silvia, Siena, Salvatore, Tabernero, Josep, Trusolino, Livio, Bernards, Rene, Bardelli, Alberto·2021·Nature Reviews Clinical Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-021-00495-z

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Research works printed but not linked: 187

  1. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015). · DOI · Paper page
  2. Remon, J. & Dienstmann, R. Precision oncology: separating the wheat from the chaff. ESMO Open 3, e000446 (2018). · DOI
  3. Banerji, U. & Workman, P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin. Oncol. 43, 436–445 (2016). · DOI
  4. Yap, T. A., Sandhu, S. K., Workman, P. & de Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514–523 (2010). A framework for evidence-based decision-making during drug discovery and development. · DOI · Paper page
  5. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012). The first evidence of the mechanism of resistance to BRAF inhibitor in BRAF-mutant CRC through feedback reactivation of the EGFR-MAPK axis. · DOI · Paper page
  6. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016). · DOI · Paper page
  7. Najgebauer, H. et al. CELLector: genomics-guided selection of cancer in vitro models. Cell Syst. 10, 424–4326 (2020). · DOI
  8. Ballard, D. H., Boyer, C. J. & Alexander, J. S. Organoids – preclinical models of human disease. N. Engl. J. Med. 380, 1981–1982 (2019). · DOI
  9. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998–1013 (2014). · DOI · Paper page
  10. Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017). · DOI · Paper page
  11. Rad, R. et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24, 15–29 (2013). · DOI · Paper page
  12. Bürtin, F., Mullins, C. S. & Linnebacher, M. Mouse models of colorectal cancer: past, present and future perspectives. World J. Gastroenterol. 26, 1394–1426 (2020). · DOI · Paper page
  13. Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014). · DOI · Paper page
  14. Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A. & Pinto, C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1–8 (2018). · DOI
  15. Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531–548 (2017). · DOI · Paper page
  16. Siravegna, G. et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin. Cancer Res. 25, 3046–3053 (2019). · DOI
  17. Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 8, 1270–1285 (2018). · DOI · Paper page
  18. Parikh, A. R. et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin. Cancer Res. 26, 1877–1885 (2020). · DOI
  19. Siravegna, G. et al. How liquid biopsies can change clinical practice in oncology. Ann. Oncol. 30, 1580–1590 (2019). · DOI · Paper page
  20. Ciardiello, D. et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat. Rev. 76, 22–32 (2019). · DOI · Paper page
  21. Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017). · DOI · Paper page
  22. Rospo, G. et al. Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Med. 11, 42 (2019). · DOI
  23. Germano, G., Amirouchene-Angelozzi, N., Rospo, G. & Bardelli, A. The clinical impact of the genomic landscape of mismatch repair-deficient cancers. Cancer Discov. 8, 1518–1528 (2018). · DOI
  24. Olson, B., Li, Y., Lin, Y., Liu, E. T. & Patnaik, A. Mouse models for cancer immunotherapy research. Cancer Discov. 8, 1358–1365 (2018). · DOI · Paper page
  25. Segal, N. H. & Saltz, L. B. Translational considerations on the outlook of immunotherapy for colorectal cancer. Curr. Colorectal Cancer Rep. 11, 92–97 (2015). · DOI
  26. Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020). · DOI · Paper page
  27. Wieduwilt, M. J. & Moasser, M. M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65, 1566 (2008). · DOI · Paper page
  28. Mendelsohn J, B. J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000). · DOI · Paper page
  29. Salomon, D. S., Brandt, R., Ciardiello, F. & Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995). · DOI · Paper page
  30. Wu, X., Fan, Z., Masui, H., Rosen, N. & Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95, 1897–1905 (1995). · DOI · Paper page
  31. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174 (2008). · DOI · Paper page
  32. Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004). The first trial demonstrating the clinical efficacy of an anti-EGFR agent in mCRC. · DOI · Paper page
  33. Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787–2799 (2003). · DOI · Paper page
  34. Chung, K. Y. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803–1810 (2005). · DOI · Paper page
  35. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995 (2006). · DOI · Paper page
  36. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008). · DOI · Paper page
  37. Segelov, E. et al. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study. J. Clin. Oncol. 34, 2258–2264 (2016). · DOI
  38. Siena, S. et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS ONE 8, e62264 (2013). · DOI
  39. Douillard, J.-Y. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697–4705 (2010). · DOI · Paper page
  40. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254–1261 (2010). · DOI · Paper page
  41. Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851–1857 (2009). · DOI · Paper page
  42. van Brummelen, E. M. J., de Boer, A., Beijnen, J. H. & Schellens, J. H. M. BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies. Oncologist 22, 864–872 (2017). · DOI
  43. Rowland, A. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br. J. Cancer 112, 1888–1894 (2015). · DOI · Paper page
  44. Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur. J. Cancer 51, 587–594 (2015). · DOI · Paper page
  45. Smith, C. G. et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res. 19, 4104–4113 (2013). · DOI
  46. Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715–721 (2009). · DOI · Paper page
  47. Peeters, M. et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 19, 1902–1912 (2013). · DOI · Paper page
  48. Karapetis, C. S. et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer–results from NCIC CTG/AGITG CO.17. Clin. Cancer Res. 20, 744–753 (2014). · DOI · Paper page
  49. Orlandi, A. et al. BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics 16, 2069–2081 (2015). · DOI
  50. Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652–2657 (2008). · DOI · Paper page
  51. Day, F. L. et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res. 19, 3285–3296 (2013). · DOI
  52. Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84–90 (2009). · DOI · Paper page
  53. Huang, L. et al. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch. Med. Sci. 10, 1–9 (2014). · DOI
  54. Sepulveda, A. R. et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 1453–1486 (2017). · DOI · Paper page
  55. Ciardiello, F. et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann. Oncol. 27, 1055–1061 (2016). · DOI
  56. Scartozzi, M. et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann. Oncol. 23, 1706–1712 (2012). · DOI · Paper page
  57. Martinelli, E. et al. AXL is an oncotarget in human colorectal cancer. Oncotarget 6, 23281–23296 (2015). · DOI
  58. Cardone, C. et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur. J. Cancer 138, 1–10 (2020). · DOI
  59. De Robertis, M. et al. Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer. Clin. Cancer Res. 23, 159–170 (2017). · DOI · Paper page
  60. Martini, G. et al. EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer. Mol. Cancer Ther. 18, 845–855 (2019). · DOI
  61. Pietrantonio, F. et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl Cancer Inst. 109, djx089 (2017). · DOI · Paper page
  62. Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann. Oncol. 28, 3009–3014 (2017). · DOI
  63. Morano, F. et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099–3110 (2019). · DOI
  64. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014). · DOI · Paper page
  65. Martini, G. et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed? Cancer Treat. Rev. 86, 102023 (2020). · DOI
  66. Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6, 147–153 (2016). · DOI · Paper page
  67. Troiani, T. N. S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V. et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin. Cancer Res. 20, 3775–3786 (2014). · DOI · Paper page
  68. Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. 29, 119–126 (2018). · DOI
  69. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015). · DOI · Paper page
  70. Siravegna, G. et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell 34, 148–1627 (2018). · DOI · Paper page
  71. Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243–249 (2019). · DOI · Paper page
  72. Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017). · DOI · Paper page
  73. Garrett, T. P. J. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495–505 (2003). · DOI · Paper page
  74. Siena, S. et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 29, 1108–1119 (2018). · DOI · Paper page
  75. Valtorta, E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod. Pathol. 28, 1481–1491 (2015). · DOI · Paper page
  76. Seo, A. N. et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE 9, e98528 (2014). · DOI · Paper page
  77. Nam, S. K. et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS ONE 11, e0151865 (2016). · DOI
  78. Ingold Heppner, B. et al. HER2/neu testing in primary colorectal carcinoma. Br. J. Cancer 111, 1977–1984 (2014). · DOI · Paper page
  79. Missiaglia, E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25, 1995–2001 (2014). · DOI · Paper page
  80. Laurent-Puig, P. et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann. Oncol. 27, vi151 (2016).
  81. Raghav, K. P. S. et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J. Clin. Oncol. 34, 3517 (2016). · DOI
  82. Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. & Wrba, F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 6, 123 (2006). · DOI
  83. Sun, S.-J. et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J. Cancer Res. Ther. 12, 323–333 (2020).
  84. Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395–1402 (2019). · DOI · Paper page
  85. Brannon, A. R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 15, 454 (2014). · doi:10.1186/s13059-014-0454-7 · Paper page
  86. Loree, J. M. et al. Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. J. Natl Cancer Inst. 110, 1409–1417 (2018). · DOI · Paper page
  87. Leto, S. M. et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin. Cancer Res. 21, 5519–5531 (2015). · DOI
  88. Martin, V. et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br. J. Cancer 108, 668–675 (2013). · DOI · Paper page
  89. Clark, J., Niedzwiecki, D., Hollis, D. & Mayer, R. Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 3584 (2003).
  90. Ramanathan, R. K. et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858–865 (2004). · DOI
  91. Sartore-Bianchi, A. et al. Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib. JAMA Oncol. 6, 927–929 (2020). · DOI
  92. Tosi, F. et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin. Colorectal Cancer 19, 256–262.e2 (2020). Three papers reporting the results of the HERACLES-A trial, investigating the combination of trastuzumab and lapatinib in HER2+ mCRC. · DOI · Paper page
  93. Sartore-Bianchi, A. et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 5, e000911 (2020). · DOI · Paper page
  94. Sakai, K. et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 98, 1498–1503 (2007). · DOI
  95. Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008). · DOI · Paper page
  96. Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016). · DOI · Paper page
  97. Siena, S. et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. (in the press).
  98. Nakamura, Y. et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study [abstract 526PD]. Ann. Oncol. 30 (Suppl. 5), v199–v200 (2019). · doi:10.1093/annonc/mdz246.004
  99. Strickler, J. H. et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial [abstract 527PD]. Ann. Oncol. 30 (Suppl. 5), v200 (2019). · DOI
  100. Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J. Clin. Oncol. 36, 350–358 (2018). · DOI · Paper page
  101. Tol, J., Nagtegaal, I. D. & Punt, C. J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98–99 (2009). · DOI · Paper page
  102. Roth, A. D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466–474 (2010). · DOI · Paper page
  103. Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016). · DOI · Paper page
  104. Clarke, C. N. & Kopetz, E. S. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J. Gastrointest. Oncol. 6, 660–667 (2015).
  105. Michaloglou, C., Vredeveld, L. C., Mooi, W. J. & Peeper, D. S. BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877–895 (2008). · DOI · Paper page
  106. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937–947 (2004). · DOI · Paper page
  107. Maughan, T. S. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377, 2103–2114 (2011). · DOI · Paper page
  108. Samowitz, W. S. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063–6069 (2005). · DOI · Paper page
  109. Tran, B. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117, 4623–4632 (2011). · DOI · Paper page
  110. Ogino, S. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin. Cancer Res. 18, 890–900 (2012). · DOI · Paper page
  111. Taieb, J. et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J. Natl Cancer Inst. 109, djw272 (2017). · DOI · Paper page
  112. Matos, I., Elez, E., Capdevila, J. & Tabernero, J. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opin. Emerg. Drugs 21, 267–282 (2016). · DOI
  113. Sinicrope, F. A. et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148, 88–99 (2015). · DOI · Paper page
  114. French, A. J. et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res. 14, 3408–3415 (2008). · DOI · Paper page
  115. Lochhead, P. et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl Cancer Inst. 105, 1151–1156 (2013). · DOI · Paper page
  116. Jones, J. C. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J. Clin. Oncol. 35, 2624–2630 (2017). · DOI · Paper page
  117. Cremolini, C. et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann. Oncol. 26, 2092–2097 (2015). · DOI
  118. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010). · DOI · Paper page
  119. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014). · DOI · Paper page
  120. Gomez-Roca, C. A. et al. Encorafenib (Lgx818), an oral Braf inhibitor, in patients (pts) with Braf V600e metastatic colorectal cancer (Mcrc): results of dose expansion in an open-label, phase 1 study [abstract 535P]. Ann. Oncol. 25 (Suppl. 4), iv182 (2014). · DOI
  121. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010). · DOI · Paper page
  122. Corcoran, R. B. et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC) [abstract 455O]. Ann. Oncol. 27 (Suppl. 6), vi150 (2016). · DOI
  123. Bendell, J. C. et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 3515 (2014). · DOI
  124. Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023–4031 (2015). · DOI · Paper page
  125. Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010). · DOI · Paper page
  126. Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019). Results from the BEACON-CRC phase III trial that led to the registration of cetuximab + encorafenib ± binimetinib in BRAF-mutant mCRC. · DOI · Paper page
  127. Grothey, A. et al. ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer [abstract LBA-5]. Ann. Oncol. 31 (Suppl. 3), S242–S243 (2020). · DOI
  128. Hong, D. S. et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 6, 1352–1365 (2016). · DOI · Paper page
  129. Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358–367 (2015). · DOI · Paper page
  130. Oddo, D. et al. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br. J. Cancer 117, 347–352 (2017). · DOI
  131. Tie, J. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int. J. Cancer 128, 2075–2084 (2011). · DOI · Paper page
  132. Fransen, K. et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25, 527–533 (2004). · DOI · Paper page
  133. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010). · DOI · Paper page
  134. Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 9, 428–436 (2013). · DOI · Paper page
  135. Schram, A. M., Chang, M. T., Jonsson, P. & Drilon, A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat. Rev. Clin. Oncol. 14, 735–748 (2017). · DOI · Paper page
  136. Pulciani, S. et al. Oncogenes in solid human tumours. Nature 300, 539–542 (1982). · DOI · Paper page
  137. Créancier, L. et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 365, 107–111 (2015). · DOI
  138. Hechtman, J. F. et al. Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF. Mol. Cancer Res. 14, 296–301 (2016). · DOI
  139. Ardini, E. et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495–1507 (2014). The first report of the sensitivity of NTRK fusion-positive CRC to TRKA inhibition. · DOI
  140. Vaishnavi, A., Le, A. T. & Doebele, R. C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5, 25–34 (2015). · DOI · Paper page
  141. Drilon, A. et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017). · DOI · Paper page
  142. Nathenson, M. et al. Activity of larotrectinib in patients with TRK fusion GI malignancies [abstract O-020]. Ann. Oncol. 29 (Suppl. 5), v107 (2018). · doi:10.1093/annonc/mdy149.019
  143. Doebele, R.C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 21, 271–282 (2020). · DOI · Paper page
  144. Sgambato, A., Casaluce, F., Maione, P. & Gridelli, C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert. Rev. Anticancer. Ther. 18, 71–80 (2018). · DOI
  145. Amatu, A. et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br. J. Cancer 113, 1730–1734 (2015). · DOI
  146. Pietrantonio, F. et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann. Oncol. 29, 1394–1401 (2018). · DOI
  147. Weaver, A. & Bossaer, J. B. Fibroblast growth factor receptor (FGFR) inhibitors: a review of a novel therapeutic class. J. Oncol. Pharm. Pract. https://doi.org/10.1177/1078155220983425 (2020). · doi:10.1177/1078155220983425
  148. Pagani, F. et al. The landscape of actionable gene fusions in colorectal cancer. Int. J. Mol. Sci. 20, 5319 (2019). · DOI
  149. Drilon, A. et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol. 27, 920–926 (2016). · DOI · Paper page
  150. Drilon, A. et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 7, 963–972 (2017). · DOI · Paper page
  151. Russo, M. et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 6, 36–44 (2016). · DOI · Paper page
  152. Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747 (2018). A thorough review on the key discoveries in NTRK fusion-positive cancers and their treatment. · DOI · Paper page
  153. Cocco, E. et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat. Med. 25, 1422–1427 (2019). The first report that MAPK reactivation through parallel signalling participates to the onset of acquired resistance to NTRK inhibitors in gastrointestinal cancers. · DOI · Paper page
  154. Pai, E. F. et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209–214 (1989). · DOI · Paper page
  155. Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst. 104, 228–239 (2012). · DOI · Paper page
  156. Strickler, J. et al. AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: results from the CodeBreak 100 phase 1 trial [abstract SO-24]. Ann. Oncol. 31 (Suppl. 3), S226 (2020). · DOI
  157. Nagasaka, M. et al. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat. Rev. 84, 101974 (2020). · DOI · Paper page
  158. Schneider, G., Schmidt-Supprian, M., Rad, R. & Saur, D. Tissue-specific tumorigenesis: context matters. Nat. Rev. Cancer 17, 239–253 (2017). · DOI · Paper page
  159. Li, M. & Belmonte, J. C. I. Organoids — preclinical models of human disease. N. Engl. J. Med. 380, 569–579 (2019). · DOI · Paper page
  160. Deming, D. A. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest. New Drugs 34, 168–175 (2016). · DOI · Paper page
  161. Neto, J. M. F. et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nat. Commun. 11, 3157 (2020). · DOI
  162. Ozkan-Dagliyan, I. et al. Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers. Cell Rep. 31, 107764 (2020). · DOI
  163. Dienstmann, R. et al. Evolving landscape of molecular prescreening strategies for oncology early clinical trials. JCO Precis. Oncol. 4, 505–513 (2020). · doi:10.1200/po.19.00398
  164. Colomer, R. et al. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 25, 100487 (2020). · DOI
  165. Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 31, 1491–1505 (2020). · DOI · Paper page
  166. Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018). The ESCAT framework to rank genomic alterations on the basis of their actionability in cancer. · DOI · Paper page
  167. Dickson, D. et al. The master observational trial: a new class of master protocol to advance precision medicine. Cell 180, 9–14 (2020). · DOI
  168. Lonardi, S. et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients [abstract]. J. Clin. Oncol. 38 (Suppl. 15), TPS4124 (2020). · DOI
  169. Reilly, N. M., Novara, L., Di Nicolantonio, F. & Bardelli, A. Exploiting DNA repair defects in colorectal cancer. Mol. Oncol. 13, 681–700 (2019). · DOI
  170. Mauri, G., Arena, S., Siena, S., Bardelli, A. & Sartore-Bianchi, A. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann. Oncol. 31, 1135–1147 (2020). · DOI
  171. Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009). · DOI · Paper page
  172. Bokemeyer, C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer 51, 1243–1252 (2015). · DOI · Paper page
  173. Tveit, K. M. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30, 1755–1762 (2012). · DOI · Paper page
  174. Patterson, S. D. et al. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408) [abstract]. J. Clin. Oncol. 31 (Suppl. 15), 3617 (2013). · DOI
  175. Seymour, M. T. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14, 749–759 (2013). · DOI · Paper page
  176. Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706–4713 (2010). · DOI · Paper page
  177. Peeters, M. et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 21, 5469–5479 (2015). · DOI · Paper page
  178. Innocenti, F. et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J. Clin. Oncol. 37, 1217–1227 (2019). · DOI · Paper page
  179. Schwartzberg, L. S. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 32, 2240–2247 (2014). · DOI · Paper page
  180. Rivera, F. et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int. J. Colorectal Dis. 32, 1179–1190 (2017). · DOI
  181. Ciardiello, F. et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann. Oncol. 25, 1756–1761 (2014). · DOI · Paper page
  182. Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J. Clin. Oncol. 39, 285–294 (2017). · DOI · Paper page
  183. Parikh, A. R. & Corcoran, R. B. Fast-TRKing drug development for rare molecular targets. Cancer Discov. 7, 934–936 (2017). · DOI
  184. Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K. & Mills, E. J. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J. Clin. 70, 125–137 (2020). · DOI · Paper page
  185. Sidaway, P. MSI-H: a truly agnostic biomarker? Nat. Rev. Clin. Oncol. 17, 68 (2020). · DOI
  186. Hyman, D. et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) [abstract]. Cancer Res. 79 (Suppl. 13), CT127 (2019). · doi:10.1158/1538-7445.am2019-ct127
  187. Jarow, J. P., Lurie, P., Ikenberry, S. C. & Lemery, S. Overview of FDA’s expanded access program for investigational drugs. Ther. Innov. Regul. Sci. 51, 177–179 (2017). · DOI · Paper page

Cited by

See all 239

Metadata

Authors
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A.
Venue
Nature Reviews Clinical Oncology
Published
2021-04-16
Volume
18
Issue
8
Pages
506-525
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3153990830
Cited by
239
References
91
FWCI
6.77
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision oncology in metastatic colorectal cancer — from biology to medicine. https://app.cochat.ai/papers/10.1038/s41571-021-00495-z
The paper
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021). Precision oncology in metastatic colorectal cancer — from biology to medicine. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00495-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.